Schedule of intangible assets


In thousands of euros	Dec. 31, 2024	June 30, 2025
Intangible assets, gross	3,947	3,993
Amortization and impairment	(3,899)	(3,908)
Intangible assets, net	48	85

Schedule of investment in Hepalys is accounted for using the equity method of accounting


(in thousands of euros)	Dec. 31, 2024		June 30, 2025
Intangible assets	16,984		15,071
Total non‑current assets	16,984		15,071
Other current assets	81		136
Cash and cash equivalents	1,785		699
Total current assets	1,866		836
Deferred assets	2		—
Total assets	18,851		15,907

Capital stock	552		532
Capital reserve	21,489		19,374
Capital surplus-others	816		786
Earnings brought forward	(1,073)		(2,987)
Net loss for the period	(3,293)		(2,068)
Treasury Shares	—		—
Shareholders’ equity	18,490		15,637
Total non‑current liabilities	—		—
Trade payables	353		270
Other current liabilities	8		0
Total current liabilities	361		270
Total equity and liabilities	18,851		15,907

Opening net assets	21,122		18,368
Loss for the period ⁽¹⁾	(3,277)		(2,158)
Revaluation of intangible assets	—		—
Other comprehensive income	(920)		(573)
Capital variations	1,566		—
Closing net assets	18,490		15,637

Group’s share in %	15	%	15	%
(in thousands of euros)
Group’s share	2,707		2,289
Elimination of unrealized profit on downstream sales	(1,604)		(1,491)
Goodwill	37		37
Carrying amount	1,139		835

Schedule of trade receivables and others break down


(In thousands of euros)	Dec. 31, 2024	June 30, 2025
3 months or less	531	10,764
Between 3 and 6 months	—	—
Between 6 and 12 months	—	—
More than 12 months	—	—
Trade receivables and others	531	10,764

Schedule of cash and cash equivalents


(in thousands of euros)	Dec. 31, 2024	June 30, 2025
Other cash equivalents⁽¹⁾	70,655	107,835
Cash at bank and at hand	25,908	14,241
Cash and cash equivalents ⁽²⁾	96,564	122,076
Bank overdrafts	—	—
Cash and cash equivalents balance from the statement of cash flows	96,564	122,076

(1)	Other cash equivalents correspond to short-term bank deposits.

(2)	Balances presented in the statement of financial position

Schedule of stock option plans

Decision of

Stock price

Outstanding

issuance by the

Grant

at grant date

at Jan 1,

Forfeited /

at June 30,

Type

Board of Directors

Date

(in euros)

2025

Issued

Exercised

Lapsed

2025

SO 2024-1

12/20/2024

01/23/2025

2.30

—

12,898,116

—

12,898,116

SO 2024-2

12/20/2024

01/23/2025

2.30

—

301,000

—

301,000

TOTAL Stock options

—

13,199,116

—

13,199,116

Schedule of movements in the period break down


(In thousands of euros)
December 31, 2024		181,250
Subscription of lease liabilities		739
Repayment of bank borrowings		(1,791)
Repayment of lease liabilities		(1,317)
Interests on royalty certificates		4,208
Capitalized interest ⁽¹⁾		5,219
Change in fair value of derivatives instruments ⁽²⁾⁽³⁾		102,640
Settlement of derivatives instruments ⁽³⁾		(158,104)
Exchange rate change		(49)
Subscription of short-term bank borrowings		3
June 30, 2025		132,798


In thousands of euros
January 1, 2024		54,083
Subscription of derivatives instruments⁽²⁾		11,809
Subscription of bank borrowings⁽¹⁾⁽²⁾		13,102
Subscription of lease liabilities		345
Issue of royalty certificates		—
Repayment of bank borrowings		(1,177)
Repayment of lease liabilities		(1,173)
Interests on royalty certificates		936
Capitalized interest		3,961
Change in fair value of derivatives instruments⁽²⁾		(8,506)
Exchange rate change		24
June 30, 2024		73,404

⁽¹⁾Net proceeds

⁽²⁾EIB’s loan and warrants.

⁽³⁾T2 New Shares - T2 BSAs of the Structured Financing

Schedule of hypothesis and results


	As of May 7, 2025
	T2 New shares	T2 BSAs	Aggregate amount
Number of instruments (in millions of units)	42.5	43.4
Number of shares per instruments	1.0	1.0
Stock price (€)	3.19	3.19
Risk free rate	Euribor 1M	Euribor 1M
Fair Value (in millions of euros)	135.5	138.1	273.7
Unit fair value	3.19	3.18
Subscription price per instrument (€)	1.35	1.34
Gross proceeds (in millions of euros)	57.4	58.2	115.6
Settlement of derivatives (in millions of euros)	78.2	79.9	158.1


	As of December 31, 2024
	T2 New shares		T2 BSAs
Number of instruments (in millions of units)	42.5		43.4
Number of shares per instruments	1.00		1.00
Stock price (€)	2.18		2.18
Maturity (months)	3.0		3.0
Volatility	58.3	%	58.3	%
Risk free rate	Euribor 3M		Euribor 3M
Expected dividends	—		—
Fair Value (in thousands of euros)	36.100		37.300
Unit fair value	0.85		0.86


	As of December 11, 2024
	(Issuance date)
	T2 New shares		T2 BSAs
Number of instruments (in millions of units)	42.5		43.4
Number of shares per instruments	1.00		1.00
Stock price (€)	2.37		2.37
Maturity (months)	3.5		3.5
Volatility	59.3	%	59.3	%
Risk free rate	Euribor 3M		Euribor 3M
Expected dividends	—		—
Fair Value (in thousands of euros)	44.000		45.400
Unit fair value	1.04		1.05

Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period


In thousands of euros	Dec. 31, 2024	June 30, 2025
Retirement benefit obligations	1,762	891
Total obligation	1,762	891

Schedule of breakdown of expense recognized for the period


In thousands of euros	June 30, 2024	June 30, 2025
Service cost for the period	(104)	(106)
Interest cost for the period	(25)	(30)
Past service cost	—	747
Benefits for the period	59	167
Total	(70)	778

Schedule of trade payables and other current liabilities


(In thousands of euros)	Dec. 31, 2024	June 30, 2025
Trade payables	32,862	34,703
Trade payables and other current liabilities	32,863	34,703

Schedule of financial assets and liabilities


	June 30, 2025
		Financial
	Book value	assets/liabilities	Financial
	on the	carried at	assets	Liabilities
	statement	fair value	carried at	carried at
	of financial	through	amortized	amortized
Financial assets	position	profit or loss	cost	cost	Fair value
Current accrued income ⁽¹⁾	4,456	—	4,456	—	4,456
Short-term deposit accounts ⁽¹⁾	24,578	—	24,578	—	24,578
Trade receivables ⁽¹⁾	10,764	—	10,764	—	10,764
Other receivables ⁽¹⁾	541	—	541	—	541
Cash and cash equivalents ⁽²⁾	122,076	—	122,076	—	122,076
Total	162,415	—	162,415	—	162,415

Financial liabilities
Long-term debt ⁽³⁾⁽⁴⁾	51,599	—	—	51,599	51,438
Derivative instruments ⁽⁵⁾	42,251	42,251	—	—	42,251
Royalty certificates liabilities⁽³⁾	33,415	—	—	33,415	111,686
Short-term debt⁽¹⁾	5,533	—	—	5,533	5,533
Trade payables⁽¹⁾	34,703	—	—	34,703	34,703
Other miscellaneous payables⁽¹⁾	4,611	—	—	4,611	4,611
Total	172,112	42,251	—	129,861	250,222

(1)	The carrying amount of short-term financial assets and liabilities at amortized cost is considered a reasonable estimate of fair value, in accordance with IFRS 7.29.

(2)	The carrying amount of cash and cash equivalents is based on level 1 valuation and corresponds to the fair value of the assets.

(3)	The fair value of royalty certificates and EIB financial debt, accounted for at amortized cost, is determined using level 3 valuation based on unobservable inputs, as described in Note 4.9 – Financial debt

(4)	The classification of other bank borrowings within the IFRS 13 fair value hierarchy corresponds to a level 2 valuation.

(5)	The fair value of derivative instruments is determined using level 3 valuation based on unobservable inputs, as described in Note 4.9 – Financial debt.


	Dec. 31, 2024
		Financial
	Book Value	assets/liabilities	Financial
	on the	carried at	assets	Liabilities
	statement	fair value	carried at	carried at
	of financial	through	amortized	amortized
Financial assets	position	profit or loss	cost	cost	Fair value
Advance payment	1,047	—	1,047	—	1,047
Current accrued income	1,574	—	1,574	—	1,574
Trade receivables	531	—	531	—	531
Other receivables	405	—	405	—	405
Cash and cash equivalents	96,564	—	96,564	—	96,564
Total	100,120	—	100,120	—	100,120

Financial liabilities
Long-term debt ⁽¹⁾	48,460	—	—	48,460	48,202
Derivative instruments	97,715	97,715	—	—	97,715
Royalty certificates liabilities	29,207	—	—	29,207	63,293
Short-term debt	5,868	—	—	5,868	5,868
Trade payables	32,862	—	—	32,862	32,862
Other miscellaneous payables	331	—	—	331	331
Total	214,444	97,715	—	116,729	248,272

(1)	See Note 4.9 – Financial debt.

Notes to the interim condensed consolidated statement of financial position

Schedule of movements in BSPCE and BSA share warrants and AGA


	Decision of issuance		Stock price	Outstanding				Outstanding
	by the Board		at grant date	at Jan 1,			Forfeited /	at June 30,
Type	of Directors	Grant Date	(in euros)	2025	Granted	Vested	Lapsed	2025
AGA 2023-1	05/25/2023	05/25/2023	2.60	525,000	—	—	(262,500)	262,500
AGA 2024-1(Tr1 - Tr2 - Tr3)	12/13/2024	01/06/2025	2.30	—	800,000	—	—	800,000
AGA 2024-2 (Tr1 - Tr2 - Tr3)	12/13/2024	01/06/2025	2.30	—	800,000	—	(541,433)	258,567
AGA 2024-3 (Tr1 - Tr2 - Tr3)	12/13/2024	01/06/2025	2.30	—	1,577,000	—	(17,500)	1,559,500
AGA 2024-4 (Tr1 - Tr2 - Tr3)	12/13/2024	01/17/2025	2.30	—	113,000	—	—	113,000
TOTAL free shares				525,000	3,290,000	—	(821,433)	2,993,567